193 related articles for article (PubMed ID: 30807641)
1. Improved treatment outcome of pembrolizumab in patients with nonsmall cell lung cancer and chronic obstructive pulmonary disease.
Shin SH; Park HY; Im Y; Jung HA; Sun JM; Ahn JS; Ahn MJ; Park K; Lee HY; Lee SH
Int J Cancer; 2019 Nov; 145(9):2433-2439. PubMed ID: 30807641
[TBL] [Abstract][Full Text] [Related]
2. Impact of mild to moderate COPD on feasibility and prognosis in non-small cell lung cancer patients who received chemotherapy.
Omote N; Hashimoto N; Morise M; Sakamoto K; Miyazaki S; Ando A; Nakahara Y; Hasegawa Y
Int J Chron Obstruct Pulmon Dis; 2017; 12():3541-3547. PubMed ID: 29270008
[TBL] [Abstract][Full Text] [Related]
3. Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial.
Shaverdian N; Lisberg AE; Bornazyan K; Veruttipong D; Goldman JW; Formenti SC; Garon EB; Lee P
Lancet Oncol; 2017 Jul; 18(7):895-903. PubMed ID: 28551359
[TBL] [Abstract][Full Text] [Related]
4. Clinical outcomes and risk factor of immune checkpoint inhibitors-related pneumonitis in non-small cell lung cancer patients with chronic obstructive pulmonary disease.
Zeng Z; Qu J; Yao Y; Xu F; Lu S; Zhang P; Yao Y; Li N; Zhou J; Wang Y
BMC Pulm Med; 2022 Dec; 22(1):458. PubMed ID: 36456932
[TBL] [Abstract][Full Text] [Related]
5. Comparison of clinical characteristics and overall survival between spirometrically diagnosed chronic obstructive pulmonary disease (COPD) and non-COPD never-smoking stage I-IV non-small cell lung cancer patients.
Lim JU; Yeo CD; Rhee CK; Kang HS; Park CK; Kim JS; Kim JW; Kim SJ; Yoon HK; Lee SH
Int J Chron Obstruct Pulmon Dis; 2019; 14():929-938. PubMed ID: 31118602
[No Abstract] [Full Text] [Related]
6. Chronic Obstructive Pulmonary Disease Alters Immune Cell Composition and Immune Checkpoint Inhibitor Efficacy in Non-Small Cell Lung Cancer.
Mark NM; Kargl J; Busch SE; Yang GHY; Metz HE; Zhang H; Hubbard JJ; Pipavath SNJ; Madtes DK; Houghton AM
Am J Respir Crit Care Med; 2018 Feb; 197(3):325-336. PubMed ID: 28934595
[TBL] [Abstract][Full Text] [Related]
7. Impact of chronic obstructive pulmonary disease on immune checkpoint inhibitor efficacy in advanced lung cancer and the potential prognostic factors.
Zhou J; Chao Y; Yao D; Ding N; Li J; Gao L; Zhang Y; Xu X; Zhou J; Halmos B; Tsoukalas N; Kataoka Y; de Mello RA; Song Y; Hu J
Transl Lung Cancer Res; 2021 May; 10(5):2148-2162. PubMed ID: 34164266
[TBL] [Abstract][Full Text] [Related]
8. Factors associated with inadequate diagnosis of COPD: On-Sint cohort analysis.
Fernández-Villar A; López-Campos JL; Represas Represas C; Marín Barrera L; Leiro Fernández V; López Ramírez C; Casamor R
Int J Chron Obstruct Pulmon Dis; 2015; 10():961-7. PubMed ID: 26028969
[TBL] [Abstract][Full Text] [Related]
9. Pembrolizumab for the treatment of nonsmall cell lung cancer: Current status and future directions.
Qin Q; Li B
J Cancer Res Ther; 2019; 15(4):743-750. PubMed ID: 31436226
[TBL] [Abstract][Full Text] [Related]
10. Prevention of clinically important deteriorations in COPD with umeclidinium/vilanterol.
Singh D; Maleki-Yazdi MR; Tombs L; Iqbal A; Fahy WA; Naya I
Int J Chron Obstruct Pulmon Dis; 2016; 11():1413-24. PubMed ID: 27445468
[TBL] [Abstract][Full Text] [Related]
11. Prevalence of and risk factors for postoperative pulmonary complications after lung cancer surgery in patients with early-stage COPD.
Kim ES; Kim YT; Kang CH; Park IK; Bae W; Choi SM; Lee J; Park YS; Lee CH; Lee SM; Yim JJ; Kim YW; Han SK; Yoo CG
Int J Chron Obstruct Pulmon Dis; 2016; 11():1317-26. PubMed ID: 27366059
[TBL] [Abstract][Full Text] [Related]
12. The impact of coexisting COPD on survival of patients with early-stage non-small cell lung cancer undergoing surgical resection.
Zhai R; Yu X; Shafer A; Wain JC; Christiani DC
Chest; 2014 Feb; 145(2):346-353. PubMed ID: 24008835
[TBL] [Abstract][Full Text] [Related]
13. Short-term effects of inhalative tiotropium/formoterol/budenoside versus tiotropium/formoterol in patients with newly diagnosed chronic obstructive pulmonary disease requiring surgery for lung cancer: a prospective randomized trial.
Bölükbas S; Eberlein M; Eckhoff J; Schirren J
Eur J Cardiothorac Surg; 2011 Jun; 39(6):995-1000. PubMed ID: 20970351
[TBL] [Abstract][Full Text] [Related]
14. Looking for the best immune-checkpoint inhibitor in pre-treated NSCLC patients: An indirect comparison between nivolumab, pembrolizumab and atezolizumab.
Passiglia F; Galvano A; Rizzo S; Incorvaia L; Listì A; Bazan V; Russo A
Int J Cancer; 2018 Mar; 142(6):1277-1284. PubMed ID: 29080213
[TBL] [Abstract][Full Text] [Related]
15. Survival impact of treatment for chronic obstructive pulmonary disease in patients with advanced non-small-cell lung cancer.
Ajimizu H; Ozasa H; Sato S; Funazo T; Sakamori Y; Nomizo T; Kuninaga K; Ogimoto T; Hosoya K; Yamazoe M; Tsuji T; Yoshida H; Itotani R; Ueno K; Kim YH; Muro S; Hirai T
Sci Rep; 2021 Dec; 11(1):23677. PubMed ID: 34880386
[TBL] [Abstract][Full Text] [Related]
16. Pembrolizumab for the treatment of non-small cell lung cancer.
Lim SH; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
Expert Opin Biol Ther; 2016; 16(3):397-406. PubMed ID: 26800463
[TBL] [Abstract][Full Text] [Related]
17. Coexistence of Emphysema With Non-small-cell Lung Cancer Predicts the Therapeutic Efficacy of Immune Checkpoint Inhibitors.
Takayama Y; Nakamura T; Fukushiro Y; Mishima S; Masuda K; Shoda H
In Vivo; 2021; 35(1):467-474. PubMed ID: 33402498
[TBL] [Abstract][Full Text] [Related]
18. Which is the optimal immunotherapy for advanced squamous non-small-cell lung cancer in combination with chemotherapy: anti-PD-1 or anti-PD-L1?
Zhang Y; Zhou H; Zhang L
J Immunother Cancer; 2018 Dec; 6(1):135. PubMed ID: 30509312
[TBL] [Abstract][Full Text] [Related]
19. Immune Checkpoint Inhibitors for Patients With Advanced Non-Small-Cell Lung Cancer: A Systematic Review.
Ellis PM; Vella ET; Ung YC
Clin Lung Cancer; 2017 Sep; 18(5):444-459.e1. PubMed ID: 28416123
[TBL] [Abstract][Full Text] [Related]
20. Prevalence and risk factors of chronic obstructive pulmonary disease in China (the China Pulmonary Health [CPH] study): a national cross-sectional study.
Wang C; Xu J; Yang L; Xu Y; Zhang X; Bai C; Kang J; Ran P; Shen H; Wen F; Huang K; Yao W; Sun T; Shan G; Yang T; Lin Y; Wu S; Zhu J; Wang R; Shi Z; Zhao J; Ye X; Song Y; Wang Q; Zhou Y; Ding L; Yang T; Chen Y; Guo Y; Xiao F; Lu Y; Peng X; Zhang B; Xiao D; Chen CS; Wang Z; Zhang H; Bu X; Zhang X; An L; Zhang S; Cao Z; Zhan Q; Yang Y; Cao B; Dai H; Liang L; He J;
Lancet; 2018 Apr; 391(10131):1706-1717. PubMed ID: 29650248
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
